<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838810</url>
  </required_header>
  <id_info>
    <org_study_id>I-Cure-2</org_study_id>
    <nct_id>NCT02838810</nct_id>
  </id_info>
  <brief_title>The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg</brief_title>
  <official_title>The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues
      (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with
      sequential treatment of pegylated interferon alpha and NAs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to optimize HBsAg clearance in CHB patients with low level HBsAg, the investigators
      enrolled patients who had received, and responded to, NAs for more than 12 months(see the
      inclusion criteria), and patients are switched to receive peginterferon alfa-2a 180
      micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment
      is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks
      course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL,
      peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg Clearance</measure>
    <time_frame>120 weeks</time_frame>
    <description>Percentage of Participants with HBsAg &lt;0.05 IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBsAg Seroconversion</measure>
    <time_frame>120 weeks</time_frame>
    <description>Percentage of Participants with HBsAg &lt;0.05 IU/mL and anti-HBsAg positive.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg &lt;1000 IU/mL and Hepatitis B virus DNA &lt;100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients do not need to change their NAs treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa</intervention_name>
    <description>peginterferon alfa-2b or peginterferon alfa-2a</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside analogues</intervention_name>
    <description>Nucleoside analogues</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>NAs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CHB patients who had received single NAs for more than 12 months.

          2. Hepatitis B e antigen (HBeAg)-negative.

          3. Hepatitis B surface antigen (HBsAg) positive and &lt;1000 IU/mL.

          4. Hepatitis B virus DNA &lt;100 IU/mL.

        Exclusion Criteria:

          1. Patients with liver cirrhosis, Hepatocellular Carcinoma or AFP &gt;2 ULN or other
             malignancies.

          2. Patients with other factors causing liver diseases.

          3. Pregnant and lactating women.

          4. Patients with concomitant HIV infection or congenital immune deficiency diseases.

          5. Patients with diabetes, autoimmune diseases.

          6. Patients with important organ dysfunctions.

          7. Patients with serious complications (e.g., infection, hepatic encephalopathy,
             hepatorenal syndrome, gastrointestinal bleeding.)

          8. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.

          9. Patients with a previous use of IFN anti hepatitis B virus treatment or have NAs drug
             resistance.

         10. Patients who can't come back to clinic for follow-up on schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiliang Gao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Zhu, Doctor</last_name>
    <phone>13826452564</phone>
    <email>0628zhuxiang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The third affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>13826452564</phone>
      <email>0628zhuxiang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhiliang Gao</investigator_full_name>
    <investigator_title>Chief director of department of infectious disease</investigator_title>
  </responsible_party>
  <keyword>peginterferon alfa</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

